DeLLphi-304: A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Study-ID: NCT05740566, 2022-502669-14

DZL Disease Area: LC

Study Type: Interventional

DZL Role: DZL recruiting center

Funding: Externally - industry

DZL Participating Sites: ARCN, BIH / Charité - Associated Partner

Start Date: 31.05.2023

Completion Date: 26.03.2028

Status: Active / not recruiting

DZL recruiting center

Disease: SCLC

NCT Number: NCT05740566

EUCT/CTIS Number: 2022-502669-14